Abstract: Objective To evaluate effect of observed serum cytokines between Fuzhenghuayu and joint capsule ursodeoxycholic acid capsules for primary biliary cirrhosis (PBC) in patients with symptoms, immune-related indicators. Methods Total of 60 patients with PBC were randomly divided into experimental group (30 cases) and control group (30 cases). Experimental group received capsules combined Fuzhenghuayu ursodeoxycholic acid capsules orally, the control group UDCA capsules orally. Patients in both groups were treated for 24 weeks. Record and analyze treatment 12 weeks and 24 weeks of patients with symptoms of clinical medicine, anti-mitochondrial antibody (AMA), anti-mitochondrial antibody-M2 subtype (AMA-M2), immunoglobulin G (IgG), immunoglobulin M (IgM), immune immunoglobulin A (IgA), immunoglobulin B (IgB), alkaline phosphatase (ALP), γ-glutamyl peptidase (GGT), ALT, AST, TBil and total cholesterol (CH), triglycerides change (TG) and other indicators. Results After 12 weeks and 24 weeks of treatment, two groups of ALT, AST, TBil, ALP, GGT, TG, CH, AMA, AMA-M2, the IgM before treatment group were improved significantly, the differences were statistically significant (P ＜ 0.05); while IgA, IgB, the IgG before treatment group showed no significant improvement, the difference was not statistically significant (P ＞ 0.05). In the experimental group therapy TCM clinical symptoms improved significantly in the 12 weeks and 24 weeks, but over the prior 12 weeks of treatment in the control group did not improve symptoms of clinical medicine, Chinese medicine treatment of 24 weeks of clinical symptoms improved slightly, but no significant difference before and after treatment (P ＞ 0.05). In the experimental group therapy TCM clinical symptoms, ALP, GGT, ALT, AST, TG, AMA-M2 significant improvement compared with the control group, the differences were statistically significant (P ＜ 0.05) in the 12 weeks and 24 weeks, while the experimental group was treated for 12 weeks AMA, IgM and TBil declined slightly compared with before treatment, compared with control group, but the difference was not statistically significant (P ＞ 0.05). When the treatment in the experimental group TCM clinical symptoms, ALP, GGT, ALT, AST, TG, AMA-M2 compared with the control group were significantly decreased, the difference was statistically significant (P ＜ 0.05) in the 24 weeks. Conclusions Fuzhenghuayu capsule combined with ursodesoxycholic acid take better effect than single ursodesoxycholic acid to PBC in symptom, ALP, GGT, ALT, AST, TG, AMA, AMA-M2, IgM, TBil, but have no different for the levels of CH, IgA, IgB, IgG.